Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

nanoparticle encapsulated AChR epitopes CNP-106

A nanoparticle-based formulation consisting of an antigenic acetylcholine receptor (AChR) peptide pool dispersed within a negatively charged polymer matrix of poly(dl-lactide-co-glycolide) (PLGA) particles, with potential immunomodulatory activity. Upon administration, nanoparticle encapsulated AChR epitopes CNP-106 binds to inflammatory cells and delivers multiple AChR epitopes, which initiates tolerogenic immune reprogramming. This may induce and promote antigen-specific tolerance against AChR, which may prevent neuromuscular junction damage and dysfunction that results from autoimmunity targeting AChR.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:CNPs encapsulating AChR peptides CNP-106
Code name:CNP 106
CNP-106
CNP106
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search